Agreement: I AgreeBody: Dear Editor
Correction
When the Collaborative Group on Hormonal Factors in Breast Cancer reviewed all the available relevant randomised evidence use of micronized progesterone as HRT doubled the risk of breast cancer ( RR 2.05, 1.38-3.56).
1 Collaborative Group on Hormonal Factors in Breast Cancer. Type and Timing of menopausal therapy and breast cancer risk individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394 1159-68. :10.1016/S0140-6736(19)31474332.
No competing Interests: YesThe following competing Interests: Electronic Publication Date: Sunday, March 20, 2022 – 11:18Highwire Comment Subject: Risk of breast cancer with HRT depends on therapy type and durationWorkflow State: ReleasedFull Title: Re: Risk of breast cancer with HRT depends on therapy type and duration
Highwire Comment Response to: Risk of breast cancer with HRT depends on therapy type and durationCheck this box if you would like your letter to appear anonymously:: Last Name: GrantFirst name and middle initial: Ellen CGEmail: ellengrant@talktalk.netAddress: Kingston-upon-Thames, SurreyOccupation: Physician and medical gynaecologistAffiliation: RetiredBMJ: Additional Article Info: Rapid response